Existing anti-angiogenic therapeutic strategies for patients with metastatic colorectal cancer progressing following first-line bevacizumab-based therapy

Figure 2 A proposed algorithm for the management of patients with metastatic colorectal cancer after disease progression following bevacizumab-based first-line therapy. Rapid progressors: Patients progressing within 3 mo after starting first-line chemotherapy. ¹In patients who did not receive irinotecan-based first-line chemotherapy and only in combination with FOLFIRI. Pts: Patients; PD: Progressive disease; CT: Chemotherapy; BEV: Bevacizumab; wt: Wild-type; mt: Mutant; EGFR: Epidermal growth factor receptor.